(Reuters) – Australia’s CSL Ltd on Wednesday entered into a collaboration and license agreement with Arcturus Therapeutics Holdings Inc to access the U.S. drug developer’s late stage self-amplifying mRNA vaccine platform technology.
The biopharmaceutical firm said it would pay Arcturus $200 million upfront in return for exclusive licence to its next generation mRNA technology to develop vaccines for influenza, COVID-19, and other respiratory viral diseases.
(Reporting by Upasana Singh in Bengaluru; Editing by Anil D’Silva)
